Phuturdex › Diseases › Ovarian neoplasm
Drugs in development · updated 30 October 2026
Ovarian neoplasm: drugs in development
As of 30 October 2026 there are 447 active clinical trials (recruiting or ongoing, phases I–III) on 411 drugs for ovarian neoplasm. 273 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 273 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Bevacizumabavastin, MVASI | II–III | 76 | NCT02839707 |
| PaclitaxelTaxol, Paxlitaxel | II–III | 66 | NCT06161025 |
| CarboplatinCarboplatine, Paraplatin | III | 62 | NCT07743164 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 46 | NCT07286266 |
| OlaparibAZD2281, Lynparza® | II–III | 34 | NCT02502266 |
| CyclophosphamideCyclophosphamid, Cytoxan | III | 28 | NCT04520074 |
| GemcitabineGemcitabin, Gemzar | III | 22 | NCT07743164 |
| CisplatinCis Platinum, Cisplatine | III | 21 | NCT05281471 |
| Pegylated liposomal doxorubicinLiposomal Doxorubicin, DOXIL | II–III | 15 | NCT02839707 |
| NiraparibZejula® | III | 14 | NCT06915025 |
| TopotecanHycamtin®, Topotecan Hospira® | II–III | 13 | NCT06161025 |
| DoxorubicinAdriamycin, Doxorubincin | III | 9 | NCT06855069 |
| OxaliplatinOxaliplatine, Oxaliplain | III | 9 | NCT01081262 |
| Nab-paclitaxelAbraxane, Nab-placlitaxel | III | 8 | NCT05257408 |
| DurvalumabMEDI4736, Imfinzi® | III | 7 | NCT03737643 |
Sorted by most advanced phase and number of active trials. Showing 15 of 138 drugs.
All 411 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Ovarian epithelial carcinoma 66 drugs
- Fallopian tube neoplasm 124 drugs
- Endometrial neoplasm 298 drugs
- Triple-negative breast neoplasm 334 drugs
- Transitional cell carcinoma 146 drugs
- Carcinoma, Endometrioid 13 drugs
- Colorectal neoplasm 534 drugs
- Lung small cell carcinoma 197 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Thyroid neoplasm 99 drugs
- Melanoma 352 drugs
- Neoplasm 671 drugs
Broader categories
- Female urogenital disease 11 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
- Endocrine gland neoplasm 3 drugs
- Genital Diseases 7 drugs
- Gonadal disease 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D010051 “Ovarian Neoplasms”.